Retatrutide

Retatrutide is a triple agonist of GIP, GLP-1, and glucagon receptors.; The program includes two basket trials (TRIUMPH-1 and -2) with nested OSA/OA protocols, one CVD-focused trial (TRIUMPH-3), and one stand-alone OA trial (TRIUMPH-4).; Type I error rate is controlled at 0.05 across weight management and basket trials.; The design allows concurrent evaluation of retatrutide for obesity, OSA, and knee OA.

Retatrutide 8 mg (pooled) led to a 26.1% reduction in total fat mass, significantly greater than placebo (4.5% reduction).; Retatrutide 4 mg and 12 mg also significantly reduced fat mass compared to placebo (15.2% and 23.2% reductions, respectively).; Adverse events were similar across groups, with gastrointestinal events most common and no deaths reported.; Lean mass loss proportion was similar to other obesity treatments, indicating no disproportionate lean mass loss with retatrutide.

Retatrutide activates GLP-1, GIP, and glucagon receptors, leading to weight reduction and improved glycemic control.; Animal studies show delayed gastric emptying, reduced food intake, and superior weight loss compared to other incretin-based therapies.; Phase I/II trials demonstrate dose-dependent weight loss, HbA1c reductions, and improvements in liver steatosis and diabetic kidney disease.; Common adverse effects are gastrointestinal and dose-related; ongoing Phase III TRIUMPH studies evaluate long-term safety and efficacy.

Semaglutide 2.4 mg results in 15-17% mean weight loss and offers cardioprotection.; Tirzepatide, a dual GLP-1/GIP agonist, leads to up to 22.5% weight loss in phase 3 trials.; Combinations like cagrisema and retatrutide are in phase 3 trials and may surpass tirzepatide in weight loss.; Agents with different mechanisms, such as bimagrumab, are in early trials to improve body composition during weight loss.

Tirzepatide (15 mg weekly) led to 17.8% weight loss at 72 weeks; semaglutide (2.4 mg weekly) to 13.9% at 68 weeks; liraglutide (3.0 mg daily) to 5.8% at 26 weeks.; Retatrutide (12 mg weekly) produced the greatest weight loss of 22.1% at 48 weeks.; Adverse events occurred in 80-97% of GLP-1 RA groups vs. 63-100% with placebo, mostly gastrointestinal (47-84% vs. 13-63%).; Serious adverse events (0-10%) and discontinuations due to AEs (0-26%) were rare.

Retatrutide is a triple agonist targeting glucagon, GIP, and GLP-1 receptors.; Clinical trials demonstrate significant body weight reduction and improved glycemic control.; Retatrutide shows promise in mitigating cardiovascular risk factors and metabolic dysfunction-associated steatotic liver disease.; Long-term safety and effects in special populations require further investigation.

Incretin agonists (e.g., liraglutide, semaglutide, tirzepatide, retatrutide) induce 15-24% weight loss but also cause rapid lean mass loss comparable to a decade or more of aging.; Supervised resistance exercise training >10 weeks can increase lean mass by approximately 3 kg and strength by 25% in men and women.; Combining aerobic exercise with liraglutide after a low-calorie diet improved weight loss maintenance compared to either alone.; Preserving lean mass during incretin therapy may reduce body weight and fat regain upon cessation of pharmacotherapy.

What is Retatrutide?

Retatrutide (LY3437943) is a synthetic peptide designed as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. Its mechanism of action integrates complementary metabolic effects: GLP-1 receptor activation enhances insulin secretion and del

How does Retatrutide work?

Triple GIP/GLP-1/glucagon receptor agonist in phase 3 trials showing the largest weight reductions of any incretin therapy to date.

What is the research status of Retatrutide?

Retatrutide is currently classified as clinical trials, with 154 research references on record. This is for research purposes only and is not medical advice.